Drug Approval Rates Decline

The Food ⁤and Drug Management (FDA)⁤ is experiencing a slowdown in ⁤drug reviews and approvals, ⁤according to ‍recent ⁢analysis. RBC Capital Markets analysts found that FDA drug approvals decreased by 14 percentage points in the third quarter of 2025 compared to the average of the‌ six preceding ​quarters-falling from 87% to 73% as reported by Stat News.

This decline is coupled with a⁤ rise in ⁤application review delays. The rate at which the FDA missed its ⁤review ⁤deadlines increased ​from an average of 4% to 11% during the same period.

Increased Rejection ​Rates Signal Potential Issues

The FDA also rejected a higher percentage of applications in the third quarter of 2025, increasing from ‍a‍ ancient average ⁤of 10% to​ 15%. A growing⁣ number of these ⁢rejections are linked to problems identified at‌ pharmaceutical ⁣manufacturing plants, ‌perhaps indicating issues with the FDA’s inspection and auditing​ processes.

Government Shutdown Exacerbates Problems

The current government ⁣shutdown is further compounding these challenges. While the FDA continues to process existing drug applications,⁣ the ⁣agency⁢ is currently unable to accept new submissions, creating a backlog that will likely extend delays ⁢once funding is restored.

This‌ situation presents significant hurdles for‍ pharmaceutical companies seeking to bring new ⁤treatments to market and could ⁢ultimately impact patient access ‌to innovative‍ therapies.